In this study, stable homogenous water colloid solution of pristine fullerene C60 was used in experiments for estimation of C60 photocytotoxicity on leukemic cells.
C60-RITC conjugate was synthesized for monitoring C60 entry into leukemic cells by confocal microscopy. Leukemic Jurkat cells could uptake fullerene C60 from the medium and retain the accumulated nanoparticles over 18 h. Combined treatment with C60 and visible light is followed by timedependent decrease of Jurkat cell viability.
Inhibition of protein tyrosine phosphorylation could be one of the mechanisms of C60 photocytotoxic effects realization. C60-mediated photodynamic effect was demonstrated also on leukemic L1210 cells both sensitive and resistant to cisplatin. Decrease of drug-resistant cell viability after C60 photoexcitation corresponded to a significant drop of mitochondrial potential.
The data obtained allow to suggest that C60 photodynamic treatment might be a potential strategy for restoring the drug-resistant leukemic cell sensitivity to induction of mitochondrial way of apoptosis.
Further to the study's findings, the implications of fullerene C60's photodynamic treatment on leukemic cells, especially those resistant to cisplatin, cannot be understated. The potential for this carbon nano compound, with its exceptional physicochemical properties, to make significant strides in cancer therapy is substantial. The fact that C60's cytotoxic effect is brought into force upon photoexcitation, causing a significant decrease of cell viability, is compelling evidence of a novel way to combat leukaemia.
Furthermore, the effect of C60-mediated photodynamic therapy on protein tyrosine phosphorylation reveals an intriguing avenue for exploration. The possibility of fullerene C60 inhibiting this essential cell function may elucidate the mechanisms behind the compound's cytotoxic effects. The correlation between this effect and decreased cell viability necessitates further research into the intricacies of C60's interaction with cell proteins.
Overall, this pioneering study on fullerene C60 introduces new horizons for photodynamic therapy, offering a beacon of hope for leukaemia treatment and potentially changing the trajectory of oncological research. Significantly, the C60 photodynamic treatment shows promise in re-sensitizing drug-resistant leukemic cells, reviving their susceptibility to apoptosis induction via mitochondrial pathways. This is a critical area of cancer therapy research that demands further investigation.